LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the combination of LBH589 and decitabine in patients age ≥
60 years with high risk Myelodysplastic Syndrome (IPSS Int-2 or High) or Acute Myeloid
Leukemia.